What it means
When a company develops a new medicine, it must prove that the medicine is safe, effective and made to a good standard. In the EU, many new medicines go through a central procedure run by the EMA.
Its expert committees review the evidence and issue a recommendation. If the EMA gives a positive opinion, the European Commission usually follows it and grants a marketing authorisation, which allows the company to sell the medicine in all EU member states.
A negative opinion can stop or delay a launch, and the company can ask for a re-examination. The agency is based in Amsterdam, having moved from London after the United Kingdom left the Union.
The EMA does not set prices or decide whether health systems will pay for a medicine. Those decisions are made country by country.
A medicine can therefore be approved but still struggle to reach patients if national authorities will not fund it. For biotech and pharmaceutical companies, the approval process is a major financial milestone.
Development costs are high and sales cannot begin until approval is granted. Investors follow expected decision dates closely, and share prices can jump or fall sharply when an opinion is published.
Finance teams in the sector build regulatory outcomes into their forecasts. They estimate the probability of approval, the likely timing and the effect of any conditions, such as extra studies after launch.
These assumptions feed into valuations, funding plans and decisions about whether to raise capital. The agency also monitors medicines after they reach the market, and it can recommend changes or restrictions if new safety information emerges.
This ongoing oversight affects costs and revenue, because a safety warning can reduce sales. Non-specialists should remember that the EMA is a regulator, not a funder or a seller.
In practice
Real-world examples.
Example
A small biotech firm submits its cancer drug to the EMA. The finance director builds a funding plan that assumes a 12-month review and holds enough cash to cover costs until the decision. He also schedules a board review of the plan once the first set of questions arrives from the agency.
Example
A fund manager in London holds shares in a pharmaceutical company awaiting an EMA opinion. She reduces her position before the decision date to limit the risk of a sharp fall. She explains to her investors that such events are hard to predict and that the position will be rebuilt after the result.
Example
A hospital group's procurement team reads an EMA approval for a new treatment. The team then asks national authorities about funding and prices before budgeting for its use. The team knows that a medicine can be authorised and still be unavailable on the hospital's formulary for months.
Formula
Calculation
Risk-adjusted value = probability of approval x value if approved
Worked example: a biotech company is awaiting the EMA's opinion on a new treatment. Analysts estimate that the medicine would be worth $500,000,000 in present value if approved, and they judge that the chance of approval is 60%.
Step 1: Value if approved = $500,000,000.
Step 2: Value if rejected = $0 (ignoring any salvage value).
Step 3: Risk-adjusted value = 60% x $500,000,000 = $300,000,000.
If a positive opinion arrives, the probability becomes close to 100% and the value moves towards $500,000,000, a rise of $200,000,000. A negative opinion would remove much of the $300,000,000. These numbers are illustrative.Case study
Seen in the real world.
Zenith Biologics is a fictional drug developer with one product awaiting a European decision. The company had cash for 14 months, and the finance team knew that a rejection would force it to raise money on poor terms.
The CFO prepared three scenarios: approval on time, approval after a delay, and rejection. She presented the board with the cash needs and share price effect in each one, so that directors could decide whether to raise funds early.
In this illustrative case, the board approved a small raise ahead of the opinion. The EMA later asked for additional data, which delayed approval by six months, but the company had enough cash to carry on. The CFO later told shareholders that early planning for delay had been worth the cost of the raise.
Watch out
Common mistakes.
- Assuming the EMA approves medicines directly, when the European Commission grants the final authorisation based on the agency's opinion.
- Thinking approval means automatic sales, when pricing and reimbursement are decided by each country.
- Ignoring the timeline, which can run for a year or more and affects a company's cash needs, especially when the agency asks for extra data.
Questions
People also ask.
Where is the EMA based?
It is based in Amsterdam, having moved from London in 2019.
Does EMA approval cover the whole EU?
Yes, a central authorisation is valid in all member states, although each country decides on pricing and funding.
Why do investors care about EMA decisions?
Approval allows a company to start selling, so it can change the value of a company dramatically. For a company with one product, the outcome may decide whether it survives.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%Related